Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Laboratoires CTRS

- PMLiVE

AstraZeneca and UK-based biotech company RQ BIO sign licencing agreement

RQ BIO has developed a portfolio of early-stage monoclonal antibodies targeting SARS-CoV-2

- PMLiVE

NICE recommends AstraZeneca’s Imfinzi for adults with non-small cell lung cancer

The treatment will be available for eligible patients in England with a stage 3 diagnosis

- PMLiVE

Phase 3 trial of AstraZeneca and Avillion’s PT027 shows promise for asthma patients

Results of MANDALA trial will be presented at the American Thoracic Society (ATS) 2022 International Conference

- PMLiVE

AstraZeneca’s Imfinzi plus chemotherapy accepted for Priority Review in the US

The drug combination offers biliary tract cancer patients a new treatment option

- PMLiVE

Sanofi launches new funding foundation

Foundation S is a philanthropic endowment fund aimed at encouraging healthier lives for future generations

- PMLiVE

Sanofi and McLaren Racing come together to maximise performance and operational excellence

The partnership will complement Sanofi’s R&D pipeline, which has 25 new launches planned over the next five years

- PMLiVE

AstraZeneca unveils plans for new US R&D centre

The site, scheduled for completion in 2026, will also include the headquarters of Alexion

- PMLiVE

New study highlights significance of chronic obstructive pulmonary disease flare-ups

COPD causes nearly 30,000 deaths in England each year, with an annual overall cost to the NHS of £1.9bn

- PMLiVE

Sanofi’s Rezurock results show positive patient outcomes

Pooled analysis of chronic graft-versus-host disease treatment demonstrates organ clinical responses correlated with meaningful changes

- PMLiVE

Sanofi begins construction on the first of two Evolutive Vaccine Facilities in Singapore

The two sites aim to improve pandemic preparedness and will have an estimated cost of $1.3bn over the next five years

- PMLiVE

AstraZeneca’s Evusheld phase 3 results show high level of protection against COVID-19

The drug decreases the risk of developing symptomatic COVID-19 by 77% among high-risk populations

- PMLiVE

Enhertu to provide patients with vital targeted therapy option

Therapy receives FDA priority review as patients with HER2-mutant metastatic non-small cell lung cancer seek alternative treatment

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links